- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cipla to pay Rs 166 crore for majority stake in Ugandan Quality Chemicals
New Delhi, Jul 24 : Drug major Cipla has re-negotiated payment terms for acquiring majority stake in Uganda's Quality Chemicals and now decided to pay USD 26 million (around Rs 166 crore) upfront to the shareholders of the African firm.
Cipla (EU), a wholly-owned subsidiary of the company, has re-negotiated the terms of the agreement and have entered into an amendment for upfront payment of the consideration amount instead of payment in tranches over a period of 5 years, the Mumbai-based company said in a statement.
"Accordingly, the revised consideration is around USD 26 million (USD 25,995,730) payable upfront upon completion of conditions precedent," it added.
In May, Cipla had inked a pact with Quality Chemicals Ltd (QCL) to acquire majority stake in it for a total consideration of over USD 30 million (around Rs 190 crore).
Cipla (EU) had entered into a definitive agreement to acquire a 51 per cent stake inQuality Chemicals Ltd (QCL) from its existing shareholders.
As per the agreement inked earlier, the cash consideration for 51 per cent stake was payable in tranches with around USD 8 million payable upfront on completion and 5 equal installments of USD 4.41 million payable at annual intervals thereafter.
QCL was incorporated in the year 1997 and is engaged in the business of import and distribution of pharmaceutical and consumer products.
Cipla (EU), a wholly-owned subsidiary of the company, has re-negotiated the terms of the agreement and have entered into an amendment for upfront payment of the consideration amount instead of payment in tranches over a period of 5 years, the Mumbai-based company said in a statement.
"Accordingly, the revised consideration is around USD 26 million (USD 25,995,730) payable upfront upon completion of conditions precedent," it added.
In May, Cipla had inked a pact with Quality Chemicals Ltd (QCL) to acquire majority stake in it for a total consideration of over USD 30 million (around Rs 190 crore).
Cipla (EU) had entered into a definitive agreement to acquire a 51 per cent stake inQuality Chemicals Ltd (QCL) from its existing shareholders.
As per the agreement inked earlier, the cash consideration for 51 per cent stake was payable in tranches with around USD 8 million payable upfront on completion and 5 equal installments of USD 4.41 million payable at annual intervals thereafter.
QCL was incorporated in the year 1997 and is engaged in the business of import and distribution of pharmaceutical and consumer products.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751
Next Story